Next Article in Journal
Nuclear Deformation in Response to Mechanical Confinement is Cell Type Dependent
Next Article in Special Issue
Role of the Hippo Pathway in Fibrosis and Cancer
Previous Article in Journal
Genetic and Real-World Clinical Data, Combined with Empirical Validation, Nominate Jak-Stat Signaling as a Target for Alzheimer’s Disease Therapeutic Development
Previous Article in Special Issue
The Roles of YAP/TAZ and the Hippo Pathway in Healthy and Diseased Skin
Article Menu

Article Versions

Export Article

Open AccessReview

GPCR-Hippo Signaling in Cancer

Children's Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China
Author to whom correspondence should be addressed.
Cells 2019, 8(5), 426;
Received: 29 March 2019 / Revised: 3 May 2019 / Accepted: 7 May 2019 / Published: 8 May 2019
(This article belongs to the Special Issue Disease and the Hippo Pathway: Cellular and Molecular Mechanisms)
PDF [731 KB, uploaded 8 May 2019]


The Hippo signaling pathway is involved in tissue size regulation and tumorigenesis. Genetic deletion or aberrant expression of some Hippo pathway genes lead to enhanced cell proliferation, tumorigenesis, and cancer metastasis. Recently, multiple studies have identified a wide range of upstream regulators of the Hippo pathway, including mechanical cues and ligands of G protein-coupled receptors (GPCRs). Through the activation related G proteins and possibly rearrangements of actin cytoskeleton, GPCR signaling can potently modulate the phosphorylation states and activity of YAP and TAZ, two homologous oncogenic transcriptional co-activators, and major effectors of the Hippo pathway. Herein, we summarize the network, regulation, and functions of GPCR-Hippo signaling, and we will also discuss potential anti-cancer therapies targeting GPCR-YAP signaling.
Keywords: G protein-coupled receptor; GPCR; Hippo pathway; YAP/TAZ; signal transduction; cancer; tumorigenesis; anti-cancer therapy G protein-coupled receptor; GPCR; Hippo pathway; YAP/TAZ; signal transduction; cancer; tumorigenesis; anti-cancer therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Luo, J.; Yu, F.-X. GPCR-Hippo Signaling in Cancer. Cells 2019, 8, 426.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top